Introducing Tarlatamab-dlle: A New Era in Oncology Treatment
The therapy offers new hope in solid tumor treatment with fewer adverse effects.
Read More
USC ALL Induction Regimen Combined With Newer TKIs Is Safe, Effective for Patients With Ph+ Disease
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.
Read More
Real-World Efficacy, Safety of Tixagevimab/Cilgavimab in Patients With Cancer After EUA Revision
The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.
Read More